Skip to main content


Advances in Therapy

Advances in Therapy OnlineFirst articles

10.06.2019 | Review Open Access

A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501

ABP 501 [United States: AMJEVITA™ (adalimumab-atto); European Union: AMGEVITA® (adalimumab)] is the first approved biosimilar to adalimumab [reference product (RP)], a monoclonal antibody (mAb) targeting tumor necrosis factor-alfa (TNF-α). ABP 501 …

10.06.2019 | Original Research

Treatment of Hypertensive and Hypercholesterolaemic Patients with the Triple Fixed Combination of Atorvastatin, Perindopril and Amlodipine: The Results of the CORAL Study

Hypertension and hypercholesterolaemia are important contributors to the development and progression of atherosclerosis. These conditions affect an ever-growing population and often coexist: hypercholesterolaemia may be present in 40–60% of …

10.06.2019 | Original Research Open Access

Development of a Patient-Reported Outcome Measure for Chronic Hypoparathyroidism

Hypoparathyroidism is a rare disorder that causes lower than normal levels of calcium in the blood due to insufficient levels of parathyroid hormone [ 1 ]. Chronic hypoparathyroidism is most often the result of neck surgeries, but can also be …

05.06.2019 | Original Research Open Access

The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia

The economic and clinical burden of diabetes in Slovakia is ever-increasing, with 7–10% of the population diagnosed with diabetes in 2017 and direct healthcare expenditure exceeding EUR 650 million [ 1 – 3 ]. This is expected to rise to over EUR …

05.06.2019 | Review Open Access

Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review

Biologics are large complex molecules, or mixtures of molecules, that have revolutionized the treatment of many chronic diseases, including diabetes, hemophilia, hepatitis, cystic fibrosis, growth deficiency, several types of cancer and autoimmune …

Aktuelle Ausgaben

Über diese Zeitschrift

Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.

Advances in Therapy is of interest to a broad audience of researchers, industry and healthcare professionals, receiving submissions from all over the world, and publishes original research and authoritative reviews focusing on new and existing therapies and interventions, areas of unmet need and general topics of interest to the medical community.

Moving forward from traditional publishing, Advances in Therapy offers a range of additional features designed to increase visibility and readership. Each paper is accompanied by a bulleted slide summary, giving a time-efficient overview of the content to a wider readership. Articles also have the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are open access and are peer reviewed to the same high standard as the article itself.

Upon acceptance of your article for publication, you will be required to pay an article processing charge of £420/$660 per typeset page. Additionally, Advances in Therapy offers an open access option for all articles submitted to the journal. If you choose open access publication you will be required to pay an additional fee of £2000/$3000 upon acceptance of your article.

Please note: Advances in Therapy's open access articles are published under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here:

For more information about the journal, please contact or see the News page for the latest journal offers.

Weitere Informationen


Neu im Fachgebiet Innere Medizin

Meistgelesene Bücher aus der Inneren Medizin

2017 | Buch

Rheumatologie aus der Praxis

Entzündliche Gelenkerkrankungen – mit Fallbeispielen

Dieses Fachbuch macht mit den wichtigsten chronisch entzündlichen Gelenk- und Wirbelsäulenerkrankungen vertraut. Anhand von über 40 instruktiven Fallbeispielen werden anschaulich diagnostisches Vorgehen, therapeutisches Ansprechen und der Verlauf …

Rudolf Puchner

2016 | Buch

Ambulant erworbene Pneumonie

Was, wann, warum – Dieses Buch bietet differenzierte Diagnostik und Therapie der ambulant erworbenen Pneumonie zur sofortigen sicheren Anwendung. Entsprechend der neuesten Studien und Leitlinien aller wichtigen Fachgesellschaften.

Santiago Ewig

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.

© Springer Medizin